PVLA — PALVELLA THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1583648 ·
Last close
$144.35
Market Cap
$2.11B
52W High
$179.95
52W Low
$72.22
ADV30
265,079
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,726,000 -24,643,000 239,402,000 193,297,000 41,478,000
Jun 2026 0 — -21,405,000 -21,870,000 253,510,000 187,803,000 36,643,000
Mar 2026 0 — -14,855,000 -15,767,000 263,759,000 206,394,000 31,446,000
Dec 2025 0 — -11,304,000 -12,714,000 59,559,000 57,982,000 31,576,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-36,513,000
Investing CF
$-62,472,000
Financing CF
$216,204,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.61
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-173,087,000
Inventory
—
Receivables
$0
ST Investments
$62,781,000
EBIT TTM
$-54,100,000
Pretax Income TTM
$-61,696,000
Interest Exp TTM
$7,596,000
Analysts
15

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -38,602,000 -41,715,000 59,559,000 31,576,000 27,983,000 -25,006,000
Dec 2024 0 -14,095,000 -17,434,000 88,234,000 25,627,000 62,607,000 -10,840,000
Dec 2023 0 -11,869,000 18,691,000 7,548,000 11,428,000 -3,880,000 -13,703,000
Dec 2022 0 -18,040,000 -27,552,000 16,524,000 39,698,000 -23,174,000 -14,840,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-61,696,000
OpCashFlow TTM
—
Assets (Latest)
$253,510,000
Forward EPS
$-8.19

Max Pain — expiry 2026-12-18

max pain strike: $135.00 · spot: $146.58 · call oi: 1,046 · put oi: 35

Peers — same industry

TickerNameMarket CapLastDaily %
AUPH Aurinia Pharmaceuticals Inc. $2.06B $15.40 —
PRGO PERRIGO Co plc $2.19B $15.76 —
IMNM Immunome Inc. $2.03B $17.18 —
BHVN Biohaven Ltd. $2.00B $13.24 —
GRFS Grifols SA $2.23B $8.63 —

News headlines (Yahoo Finance, 1h cache)

Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
2026-11-18 22:00 · Yahoo
Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
2026-11-05 23:16 · Yahoo
Palvella Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 22:30 · Yahoo
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call
2026-11-05 22:14 · Yahoo
Palvella (PVLA) Q3 2026 Earnings Call Transcript
2026-11-05 19:33 · Yahoo
Palvella Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:48 · Yahoo
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:30 · Yahoo
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
2026-11-03 12:30 · Yahoo
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
2026-10-29 11:30 · Yahoo
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
2026-10-28 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.